736 related articles for article (PubMed ID: 25586203)
1. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.
Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M
J Med Econ; 2015 Jun; 18(6):399-409. PubMed ID: 25586203
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients.
Amin A; Jing Y; Trocio J; Lin J; Lingohr-Smith M; Graham J
J Med Econ; 2014 Nov; 17(11):763-70. PubMed ID: 25078794
[TBL] [Abstract][Full Text] [Related]
3. Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.
Deitelzweig S; Amin A; Jing Y; Makenbaeva D; Wiederkehr D; Lin J; Graham J
J Med Econ; 2013 Sep; 16(9):1163-8. PubMed ID: 23869941
[TBL] [Abstract][Full Text] [Related]
4. Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population.
Amin A; Stokes M; Makenbaeva D; Wiederkehr D; Wu N; Lawrence JH
J Med Econ; 2014 Nov; 17(11):771-81. PubMed ID: 25133458
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.
Zheng Y; Sorensen SV; Gonschior AK; Noack H; Heinrich-Nols J; Sunderland T; Kansal AR
Clin Ther; 2014 Dec; 36(12):2015-2028.e2. PubMed ID: 25438722
[TBL] [Abstract][Full Text] [Related]
6. Estimated medical cost reductions associated with apixaban in real-world patients with non-valvular atrial fibrillation.
Amin A; Stokes M; Wu N; Gatt E; Makenbaeva D; Wiederkehr D; Boulanger L
J Med Econ; 2013 Oct; 16(10):1193-202. PubMed ID: 23883416
[TBL] [Abstract][Full Text] [Related]
7. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
[TBL] [Abstract][Full Text] [Related]
8. Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials.
Deitelzweig S; Amin A; Jing Y; Makenbaeva D; Wiederkehr D; Lin J; Graham J
J Med Econ; 2012; 15(4):776-85. PubMed ID: 22449118
[TBL] [Abstract][Full Text] [Related]
9. [Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation].
Rudakova AV; Tatarskiĭ BA
Kardiologiia; 2014; 54(7):43-52. PubMed ID: 25177813
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
[TBL] [Abstract][Full Text] [Related]
11. Pharmacoeconomic evaluation of dabigatran, rivaroxaban and apixaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement in Spain.
Gómez-Outes A; Avendaño-Solá C; Terleira-Fernández AI; Vargas-Castrillón E
Pharmacoeconomics; 2014 Sep; 32(9):919-36. PubMed ID: 24895235
[TBL] [Abstract][Full Text] [Related]
12. New oral anticoagulants for the treatment of venous thromboembolism.
Agnelli G; Becattini C; Franco L
Best Pract Res Clin Haematol; 2013 Jun; 26(2):151-61. PubMed ID: 23953903
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation.
Harrington AR; Armstrong EP; Nolan PE; Malone DC
Stroke; 2013 Jun; 44(6):1676-81. PubMed ID: 23549134
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation.
Kansal AR; Zheng Y; Pokora T; Sorensen SV
Best Pract Res Clin Haematol; 2013 Jun; 26(2):225-37. PubMed ID: 23953910
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
Coyle D; Coyle K; Cameron C; Lee K; Kelly S; Steiner S; Wells GA
Value Health; 2013 Jun; 16(4):498-506. PubMed ID: 23796283
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
Rollins BM; Silva MA; Donovan JL; Kanaan AO
Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
[TBL] [Abstract][Full Text] [Related]
17. Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis.
Rognoni C; Marchetti M; Quaglini S; Liberato NL
Clin Drug Investig; 2014 Jan; 34(1):9-17. PubMed ID: 24135964
[TBL] [Abstract][Full Text] [Related]
18. Venous thromboembolism management: where do novel anticoagulants fit?
Spyropoulos AC; Turpie AG
Curr Med Res Opin; 2013 Jul; 29(7):783-90. PubMed ID: 23659584
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation.
Wisløff T; Hagen G; Klemp M
Pharmacoeconomics; 2014 Jun; 32(6):601-12. PubMed ID: 24715603
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation.
Canestaro WJ; Patrick AR; Avorn J; Ito K; Matlin OS; Brennan TA; Shrank WH; Choudhry NK
Circ Cardiovasc Qual Outcomes; 2013 Nov; 6(6):724-31. PubMed ID: 24221832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]